ClinicalTrials.gg
RecruitingNCT07322263Updated Apr 17, 2026

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

A Phase 2 interventional study of Intravesical Gemcitabine and Docetaxel in Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) and Urothelial Carcinoma, sponsored by Michael A. O'Donnell. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Michael A. O'Donnell · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
174
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States — 39 open to participants now, 60 under way, 15 of them phase 3. Non-Muscle Invasive Bladder Neoplasms · United States.

Planned enrollment
26th of 93
174 · median 55
Started
2026
with 8 others
Phase 2
20 of 114
8 open now
Primary completion
2033-01
later than 57 of 59 live
Registered
105th of 114
by date

Among the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, this one is the 26th largest by planned enrollment of the 93 interventional ones that give a count, is one of 9 that started in 2026, is one of 20 in phase 2, reaches primary completion later than 57 of the 59 other live ones, and was the 105th registered.

Non-Muscle Invasive Bladder Neoplasms

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Open to participants now

39 of the 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Non-Muscle Invasive Bladder Neoplasms studies recruiting now, 78 (84%) set no upper age limit and 5 (5%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 114 studies in Non-Muscle Invasive Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn whether a combination of two chemotherapy drugs, Gemcitabine and Docetaxel, can treat high-grade non-muscle-invasive bladder cancer (HG-NMIBC) in adults whose cancer failed conventional BCG therapy. The drugs are given directly into the bladder (intravesically), one immediately after the other.

The study will also assess the safety of this treatment.

The main questions it aims to answer are:

Can this drug combination effectively treat HG-NMIBC that did not respond to BCG and help prevent the cancer from coming back, offering long-term protection? What side effects or medical issues do participants experience during treatment?

Researchers will evaluate this non-surgical approach as a potential alternative to bladder removal surgery (radical cystectomy), with the goal of validating it as a bladder-sparing option in this setting.

Participants will:

  • Go through a screening process, including tumor removal and imaging tests
  • Receive weekly bladder treatments with Gemcitabine followed by Docetaxel for 6 weeks
  • If the cancer responds, continue with similar once monthly treatments (maintenance therapy) for up to 2 years
  • Attend regular check-ups, including bladder exams, urine tests, biopsies, and optional quality-of-life surveys
  • Possibly receive a second 6-week treatment cycle if the cancer returns early
  • Be followed for up to 5 years to monitor long-term outcomes
Read the detailed description

The primary objective of this study is to evaluate the efficacy of intravesical sequential Gemcitabine and Docetaxel in patients with BCG-unresponsive, high-grade, non-muscle-invasive bladder cancer (HG-NMIBC). Efficacy will be measured by the complete response (CR) rate at approximately 3 months for patients with carcinoma in situ (CIS), and by the disease-free rate from high-grade disease at 3 months for patients with high-grade papillary Ta/T1 disease. CR will be confirmed through cystoscopy, urine cytology, and bladder biopsy. Disease-free rate in patients with high-grade papillary disease will be assessed by non-positive cytology and the absence of visible tumor (biopsy optional).

Two distinct patient cohorts will be recruited for this trial:

Arm A: Patients with CIS, either alone or with concurrent papillary tumors Arm B: Patients with high-grade papillary tumors (Ta and/or T1) without CIS

Secondary objectives include characterizing the safety and toxicity profile of the treatment and evaluating additional efficacy outcomes such as high-grade recurrence-free survival (HGRFS), recurrence-free survival (RFS), progression-free survival (PFS), cystectomy-free survival (CFS), cancer-specific survival (CSS), overall survival (OS), and quality of life (QoL).

The study will also assess outcomes in patients who experience early bladder cancer recurrence without progression and undergo a second 6-week induction cycle.

This is a prospective, two-arm, multicenter cohort study conducted nationally and internationally. Participants will receive intravesical Gemcitabine immediately followed by Docetaxel once weekly for 6 weeks (induction phase), followed by similar once monthly treatments for up to 24 months (maintenance phase). Patients will be followed for up to 5 years to assess long-term outcomes.

03

Conditions studied

  • Bladder Cancer
  • Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Urothelial Carcinoma
  • Carcinoma in Situ (CIS)
  • High-Grade Papillary Bladder Tumors
  • BCG-Unresponsive Bladder Cancer
  • Ta Stage Bladder Cancer
  • T1 Stage Bladder Cancer
  • BCG-Refractory Bladder Cancer
  • High-Risk NMIBC
  • Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)

Keywords

  • Non-Muscle Invasive Bladder Cancer (NMIBC)
  • Urothelial Carcinoma
  • Carcinoma in Situ (CIS)
  • High-Grade Papillary Bladder Tumors
  • BCG-Unresponsive Bladder Cancer
  • Intravesical Chemotherapy
  • Gemcitabine
  • Docetaxel
  • Sequential Gemcitabine and Docetaxel
  • Bladder-Sparing Therapy
  • Radical Cystectomy Alternative
  • Prospective Cohort Study
  • Recurrence-Free Survival
  • Progression-Free Survival
  • Cystectomy-Free Survival
  • Cancer-Specific Survival
  • Quality of Life (QoL)
  • FDA-Defined BCG Unresponsive Criteria
  • ECOG Performance Status
  • Multicenter International Trial
  • Bladder Preservation
04

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

295 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 127 are open to participants now.

This study's planned enrollment of 174 is above the median of 61 across 232 interventional studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

This is the only study on the registry with Michael A. O'Donnell as lead sponsor.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

confirmed diagnosis of urothelial carcinoma of the bladder without synchronous or metachronous upper tract involvement or prostatic urethral involvement. Subjects with negative upper tract imaging within 6 months of the study start and visually normal prostates are potentially eligible. Those with a history of suspicious upper tract cytology or suspicious prostatic urethra visually will require additional upper tract washes and/or to rule out concurrent extravesical disease.

Eligible bladder cancer presentations include:

  • Carcinoma in situ (CIS), with or without non-muscle-invasive stage Ta or T1 tumors of any grade.
  • High-Grade Papillary tumors (stages Ta and/or T1) without CIS.
  • All visible bladder tumors must be completely resected within 8 weeks prior to initiating intravesical Gem/Doce therapy.
  • If more than 8 weeks have passed since diagnosis or resection of index bladder CIS ± non-invasive tumor (pTa or T1 tumors), an office cystoscopy must be performed within 8 weeks of Gem/Doce initiation to confirm no visible tumor regrowth.

BCG-Unresponsive Disease as defined by any of the following FDA-accepted criteria:

  • Occurrence of high-grade, stage T1 cancer after at least 5/6 weekly BCG induction treatments.
  • Occurrence of CIS within 12 months, or high-grade papillary disease, stage Ta/T1, within 6 months after an "adequate" course of BCG therapy.

An "adequate" course of BCG includes at least 5/6 weekly BCG induction treatments and at least 2/3 weekly BCG maintenance or 2/6 weekly BCG re-induction treatments.

  • N.B: Physician may have some flexibility (+/- 1 month) in the use of 6 and 12 months to define BCG-unresponsive NMIBC.
  • N.B: Once a patient has been correctly defined as having BCG-unresponsive disease, they will be considered to always be BCG-unresponsive for the purpose of this study. In other words, there is no restriction as to when the BCG-unresponsive term was assigned.

    • The occurrence of low-grade (LG) Ta disease will not be considered a HG relapse event given its prognosis is much more favorable that HG disease. However, all LG tumor must be completely resected before continuing with Gemcitabine/Docetaxel therapy.
    • Subjects must be eligible for radical cystectomy and decline this standard of care treatment or not be a surgical candidate for radical cystectomy (as appropriate) based on other comorbidities.
    • All grossly visible disease in the bladder must be fully resected with pathologic stage and grade assessed at the local study institution. Local pathologists are strongly encouraged to use the current LG and HG AJCC criteria.

NB: For institutions that still use the 3-tiered grading system, Ta Gr1 and Gr 2 will be considered LG while any Ta Gr3 or T1 Gr2 or Gr3 will be considered HG.

  • Patients enrolled in other clinical trials must have received their last treatment at least 8 weeks prior to enrollment if the treatment was an intravesical agent. If the treatment included a systemic immune-modulating agent (e.g. anti-PD(L)-1 or anti CTLA4) then at least two dosing intervals must have elapsed untreated before the patient is eligible.
  • Age > 18 and must be able to read, understand and sign the local .
  • Patients must have an (ECOG) performance Status of 2 or less, including patients who are not surgical candidates due to comorbid conditions.
  • Women of must have a negative pregnancy test at screening.
  • All patients of childbearing potential must be willing to consent to using effective , i.e., IUD, Birth control pills, Depo-Provera, and/or condoms while on treatment and for 3 months after their last Gemcitabine/Docetaxel treatment.
  • No intravesical or upper tract topical therapy within 8 weeks of study entry.
  • Must be willing and able to comply with all protocol requirements.
  • Should have a Complete Blood Count (CBC) with differential before the index tumor resection or biopsy (within 30 days) and/or within 14 days before starting Gemcitabine/Docetaxel therapy.
  • Must be willing and able to give informed consent and any authorizations required by the local Institutional Review Board (IRB) for participation in this study.

Exclusion criteria

Exclusion Criteria:

  • History or concurrent Stage T2 or greater urothelial cancer.
  • History or concurrent upper tract or prostatic urethral cancer (no suspicious or positive upper tract cytology and negative upper tract imaging within 6 months of study entry; visually normal or absent prostatic urethra by cystoscopy).
  • History or concurrent variant bladder cancer histology including squamous cell carcinoma, adenocarcinoma, small cell carcinoma, plasmacytoid carcinoma, nested urothelial carcinoma, sarcomatoid carcinoma, squamous, glandular, carcinoma and others. Select urothelial carcinoma with favorable micropapillary differentiation is permitted (see above).
  • Active other excluding indolent or well-controlled prostate cancer, basal or squamous cell skin cancers or non-invasive cancer of the cervix are permitted so long as they are not expected to impact 3-year survival outcomes.
  • History of severe reaction (>= grade 3) to Gemcitabine and/or Docetaxel.
  • History of severe hypersensitivity reaction (>= grade 3) to Polysorbate 80 containing drugs (Docetaxel is formulated with Polysorbate 80)
  • Concurrent treatment with any intravesical or systemic chemotherapeutic agent (8-week washout required).
  • Treatment with a within 2 treatment cycles of enrollment.
  • Major surgery within 3 months of enrollment.
  • Inadequate organ and bone marrow function as evidenced by:

    1. ≤8.0 g/dL.
    2. ≤1.5 x 109/L.
    3. count ≤80 x 109/L.
    4. /SGOT and/or ALT/SGPT ≥3.0 x .
    5. Total >1.5 x ULN excepting known benign Gilbert's Disease.
    6. Serum creatinine >2.0 x ULN.

    i. If creatinine 1.5 - 2.0 x ULN, will be calculated according to formula and patients with creatinine clearance \<30 mL/min should be excluded.

  • History of radiation to the pelvis.
  • History of difficult catheterization that in the opinion of the Investigator will prevent safe and/or reliable administration of the intravesical agents.
  • History of interstitial cystitis or current inability to hold \~ 2 ounces of fluid in the bladder for the expected 60-minute retention time (assistive medication and/or techniques (gravity reflux; split dosing) are permitted).
  • Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy (3- week documented clearance required).
  • Known (HIV), , or infection.
  • Recent Covid infection within 30 days of enrollment or currently symptomatic of Covid-related illnesses.
  • Significant cardiovascular risk (e.g., coronary stenting within 8 weeks, myocardial infarction within 6 months).
  • Women who are pregnant or lactating.
  • Participation in any other research protocol involving administration of an agent within 6 weeks of study entry (8-week washout required)
  • Any other major or unstable medical condition that in the Investigator's opinion, could affect patient performance status, ability to receive the intravesical therapy and/or during the five years of intended study participation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
174 participants (estimated)

Study arms

  • Experimental
    Arm A

    High-grade non-muscle-invasive bladder cancer (HG NMIBC) with carcinoma in situ (CIS), either as pure CIS or concurrent with papillary tumors.

    Drug: Intravesical Gemcitabine and Docetaxel

  • Experimental
    Arm B

    High-grade non-muscle-invasive bladder cancer (HG NMIBC) with high-grade papillary tumors (stages Ta and/or T1) without carcinoma in situ (CIS).

    Drug: Intravesical Gemcitabine and Docetaxel

Interventions

  • DrugIntravesical Gemcitabine and Docetaxel

    Drug page: DocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sequential intravesical administration of Gemcitabine (1000mg) followed by Docetaxel (37 mg), delivered via sterile urethral catheter. Each drug is retained in the bladder for 60 minutes per instillation. The treatment consists of a 6-week induction phase (weekly instillations), followed by a 24-month maintenance phase (monthly instillations). This regimen is designed for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), including carcinoma in situ (CIS) and high-grade papillary tumors (Ta/T1). The study evaluates efficacy, tolerability, and bladder preservation outcomes.

07

What researchers measure

Primary outcomes

  1. Efficacy of Intravesical Gemcitabine/Docetaxel in BCG-Unresponsive Carcinoma In Situ NMIBC

    To determine the efficacy of intravesical Gemcitabine/Docetaxel in patients with BCG-unresponsive carcinoma in situ (CIS) urothelial bladder carcinoma, as measured by the complete response (CR) rate (%) at approximately 3 months. CR will be determined through mandatory cystoscopy, urine cytology, and biopsy for those with CIS.

    Time frame: 3 months

  2. Efficacy of Intravesical Gemcitabine/Docetaxel in BCG-Unresponsive Papillary NMIBC

    To determine the efficacy of intravesical Gemcitabine/Docetaxel in patients with BCG-unresponsive papillary urothelial bladder carcinoma, as measured by high-grade recurrence-free survival (HG RFS) rate (%) at approximately 3 months. Non-positive cytology and non-suspicious visual cystoscopic findings will determine lack of HG disease for subjects entering this study with papillary tumors (HG Ta T1).

    Time frame: 3 months

Secondary outcomes

  1. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess duration of complete response for CIS +/- papillary TaT1 in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  2. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess high-grade recurrence-free survival (HGRFS) for HG papillary only TaT1 in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  3. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess recurrence-free survival (RFS) in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  4. Long Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess progression-free survival (PFS) in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  5. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess cystectomy-free survival (CFS) in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  6. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess cancer-specific survival (CSS) in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  7. Long-Term Efficacy of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC

    To assess overall survival in month

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

Other outcomes

  1. Safety of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC: Adverse Event Analysis

    To assess the incidence (%) of adverse events

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  2. Safety of Intravesical Sequential Gemcitabine/Docetaxel in BCG-Unresponsive NMIBC: Adverse Event Analysis

    To assess the severity of adverse events (Common Terminology Criteria for Adverse Events (CTCAE)) (Grade I-IV)

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

  3. Change in Health-Related Quality of Life Measured by FACT-Bladder (FACT-Bl)

    The Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) is a validated, patient-reported outcome measure assessing health-related quality of life in bladder cancer. It includes the FACT-G core domains: Physical Well-Being (PWB), Social/Family Well-Being (SWB), Emotional Well-Being (EWB), Functional Well-Being (FWB) plus a Bladder Cancer Subscale (BLCS). Score (range: 0-160). Higher scores indicate better quality of life.

    Time frame: Up to 60 months (5 years), with assessments at baseline, Week 6 of induction, and at key evaluation points: 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months.

  4. Change in Health-Related Quality of Life Measured by FACT-General (FACT-G)

    The Functional Assessment of Cancer Therapy-General (FACT-G) is a validated, oncology-generic patient-reported outcome covering Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. Total Score Range: 0-108; higher scores indicate better quality of life.

    Time frame: Up to 60 months (5 years), with assessments at baseline, Week 6 of induction, and at key evaluation points: 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months.

  5. Change in Health-Related Quality of Life Using EQ-5D™

    EQ-5D™ is a validated instrument assessing five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It includes a descriptive system and a visual analog scale (VAS). Index Score (U.S. value set): Range -0.573 to 1.000; higher scores indicate better health status. VAS: Range 0-100; higher scores indicate better perceived health

    Time frame: Up to 60 months (5 years), with assessments at baseline, Week 6 of induction, and at key evaluation points: 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months.

  6. High-Grade Disease-Free Rate (HG-DFR) in Patients Re-Induced With Gemcitabine/Docetaxel After Recurrence

    To determine the efficacy of intravesical sequential Gemcitabine/Docetaxel in patients re-induced after recurrence of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), as measured by the high-grade disease-free rate (HG-DFR, %) at prespecified time points.

    Time frame: Up to 60 months (5 years) from initiation of treatment, with key evaluations at 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, and 60 months

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Ben-David R, Tillu N, Alerasool P, Bieber C, Ranti D, Tolani S, Eisenhauer J, Chung R, Lavallee E, Waingankar N, Attalla K, Wiklund P, Mehrazin R, Anderson CB, Sfakianos JP. Induction and maintenance of sequential intravesical gemcitabine/docetaxel for intermediate and high-risk non-muscle invasive bladder cancer with different dosage protocols. World J Urol. 2024 May 11;42(1):315. doi: 10.1007/s00345-024-04992-5. PubMed 38734774 ↗
  • Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer. Urol Oncol. 2020 Feb;38(2):40.e17-40.e24. doi: 10.1016/j.urolonc.2019.07.022. Epub 2019 Aug 28. PubMed 31473090 ↗
  • McElree IM, Mott SL, O'Donnell MA, Packiam VT. Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer. BJU Int. 2024 Jun;133(6):671-673. doi: 10.1111/bju.16208. Epub 2023 Oct 26. No abstract available. PubMed 37858923 ↗
  • Alghafees M, Chakra MA, Alkhayal A, Moussa M, Alkhamees M, Alsaikhan B, Alasker A, Alsayyari A, Alsaghyir A, Alkahtani A, O'Donnell MA. Saudi urologists' treatment pattern for high-risk Bacillus Calmette-Guerin naive and Bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer. Urol Ann. 2025 Jan-Mar;17(1):58-63. doi: 10.4103/ua.ua_43_24. Epub 2025 Jan 18. PubMed 40051987 ↗
  • Abou Chakra M, Shore ND, Dillon R, O'Donnell MA. US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guerin-Unresponsive and Bacillus Calmette-Guerin-Exposed Nonmuscle-Invasive Bladder Cancer. Urol Pract. 2024 Jan;11(1):97-107. doi: 10.1097/UPJ.0000000000000481. Epub 2023 Oct 30. PubMed 37903746 ↗
  • Abou Chakra M, Packiam VT, Duquesne I, Peyromaure M, McElree IM, O'Donnell MA. Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now? Expert Opin Pharmacother. 2024 Feb;25(2):203-214. doi: 10.1080/14656566.2024.2310073. Epub 2024 Jan 30. PubMed 38264853 ↗
  • McElree IM, Steinberg RL, Mott SL, O'Donnell MA, Packiam VT. Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer. JAMA Netw Open. 2023 Feb 1;6(2):e230849. doi: 10.1001/jamanetworkopen.2023.0849. PubMed 36853609 ↗
  • Yim K, Melnick K, Mott SL, Carvalho FLF, Zafar A, Clinton TN, Mossanen M, Steele GS, Hirsch M, Rizzo N, Wu CL, Mouw KW, Wszolek M, Salari K, Feldman A, Kibel AS, O'Donnell MA, Preston MA. Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol. 2023 Nov;41(11):458.e1-458.e7. doi: 10.1016/j.urolonc.2023.06.018. Epub 2023 Sep 9. PubMed 37690933 ↗
  • Chevuru PT, McElree IM, Mott SL, Steinberg RL, O'Donnell MA, Packiam VT. Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol. 2023 Mar;41(3):148.e1-148.e7. doi: 10.1016/j.urolonc.2022.10.030. Epub 2022 Nov 28. PubMed 36456454 ↗
  • Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer. J Urol. 2020 May;203(5):902-909. doi: 10.1097/JU.0000000000000688. Epub 2019 Dec 10. PubMed 31821066 ↗
  • Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. PubMed 34051177 ↗
  • Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients. Eur J Cancer. 2024 Mar;199:113530. doi: 10.1016/j.ejca.2024.113530. Epub 2024 Jan 11. PubMed 38295556 ↗
  • Cookson MS, Chang SS, Lihou C, Li T, Harper SQ, Lang Z, Tutrone RF. Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder. Ther Adv Urol. 2014 Oct;6(5):181-91. doi: 10.1177/1756287214541798. PubMed 25276228 ↗
  • Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guerin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5. PubMed 38704840 ↗
  • Necchi A, Roumiguie M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun;25(6):720-730. doi: 10.1016/S1470-2045(24)00178-5. Epub 2024 May 10. PubMed 38740030 ↗
  • Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar;163(3):761-7. PubMed 10687972 ↗
  • Al Hussein Al Awamlh B, Chang SS. Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer. Curr Oncol Rep. 2023 Feb;25(2):83-91. doi: 10.1007/s11912-022-01350-9. Epub 2022 Dec 26. PubMed 36571706 ↗
  • Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW, Donat SM. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009 Jan;55(1):164-74. doi: 10.1016/j.eururo.2008.07.031. Epub 2008 Jul 18. PubMed 18675501 ↗
  • Novara G, Catto JW, Wilson T, Annerstedt M, Chan K, Murphy DG, Motttrie A, Peabody JO, Skinner EC, Wiklund PN, Guru KA, Yuh B. Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy. Eur Urol. 2015 Mar;67(3):376-401. doi: 10.1016/j.eururo.2014.12.007. Epub 2015 Jan 2. PubMed 25560798 ↗
  • Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct;196(4):1021-9. doi: 10.1016/j.juro.2016.06.049. Epub 2016 Jun 16. PubMed 27317986 ↗
  • Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC, Kirkby E, McKiernan JM, Schuckman AK. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024 Apr;211(4):533-538. doi: 10.1097/JU.0000000000003846. Epub 2024 Jan 24. PubMed 38265030 ↗
  • Broughton EI, Chun DS, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Treatment and disease management patterns for bacillus Calmette-Guerin unresponsive nonmuscle invasive bladder cancer in North America, Europe and Asia: A real-world data analysis. Curr Urol. 2022 Sep;16(3):147-153. doi: 10.1097/CU9.0000000000000072. Epub 2022 Aug 2. PubMed 36204362 ↗
  • Broughton EI, Gooden KM, Mycock KL, Rajkovic I, Taylor-Stokes G. Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). BMC Urol. 2022 Feb 26;22(1):27. doi: 10.1186/s12894-022-00959-z. PubMed 35219307 ↗
  • Collacott H, Krucien N, Heidenreich S, Catto JWF, Ghatnekar O. Patient Preferences for Treatment of Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment. Eur Urol Open Sci. 2023 Jan 31;49:92-99. doi: 10.1016/j.euros.2022.12.016. eCollection 2023 Mar. PubMed 36874596 ↗
  • Moussa M, Abou Chakra M, Shore ND, Papatsoris A, Farahat Y, O'Donnell MA. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists. Arch Ital Urol Androl. 2024 Mar 19;96(1):12244. doi: 10.4081/aiua.2024.12244. PubMed 38502039 ↗
  • Joudi FN, Smith BJ, O'Donnell MA, Konety BR. Contemporary management of superficial bladder cancer in the United States: a pattern of care analysis. Urology. 2003 Dec;62(6):1083-8. doi: 10.1016/s0090-4295(03)00765-9. PubMed 14665360 ↗

Individual participant data

Plan to share: No — At this time, there are no plans to share individual participant data (IPD) due to institutional data governance policies, privacy considerations, and the absence of a formal data-sharing infrastructure. Requests for data may be considered on a case-by-case basis following study completion and publication.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jan 2033, 80 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Jan 7, 2026
StartActual
Apr 10, 2026
Primary completionEst.
Jan 1, 2033
CompletionEst.
Jan 1, 2033
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07322263
Lead sponsor
Michael A. O'Donnell
Responsible party
Michael A. O'Donnell (Professor, University of Iowa) — Sponsor-investigator
First posted
Jan 7, 2026
Start date
Apr 10, 2026
Primary completion
Jan 1, 2033 (estimated)
Completion
Jan 1, 2033 (estimated)
Last update
Apr 17, 2026

Study contacts

Denise Juhr, BS
Contact
denise-juhr@uiowa.edu
(319) 467-6313
Mohamad Abou Chakra, MD
Contact
mohamad-abouchakra@uiowa.edu
319-467-7053
Michael A O'Donnell, MD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion